https://scholars.lib.ntu.edu.tw/handle/123456789/581989
Title: | Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B | Authors: | Chien R.-N. Peng C.-Y. JIA-HORNG KAO Hu T.-H. Lin C.-C. Hu C.-T. Chen C.-Y. Hsieh T.-Y. Lin H.-C. Chuang W.-L. |
Keywords: | Chronic hepatitis B; Entecavir; Lamivudine; Patient adherence; Telbivudine | Issue Date: | 2014 | Journal Volume: | 29 | Journal Issue: | 1 | Start page/Pages: | 185-192 | Source: | Journal of Gastroenterology and Hepatology (Australia) | Abstract: | Background and Aims: Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment na?ve chronic hepatitis B (CHB) patients. However, little is known about the treatment modification and adherence on such patients with prolonged NA treatment. Methods: In this multicenter observational study, a total of 600 NA-na?ve Taiwanese CHB patients aged 16 years and older were enrolled. The 600 patients were retrospectively identified by their NA treatment history from August 2008 to July 2009; this cohort was prospectively followed up over 3 years. During the 3-year period, incidence of treatment modifications, reasons for modification, and rate of adherence were evaluated. Results: Among the 583 evaluable patients, the initial NA treatment included entecavir (ETV) in 468 patients, telbivudine (LdT) in 67, and lamivudine (LVD) in 48. During the 3-year treatment, 9.0% of ETV-treated patients, 38.8% of LdT-treated patients, and 54.2% of LVD-treated patients had treatment modification. The main reasons for treatment modification were fulfilling stopping criteria in the ETV group (40.5%) and virological breakthrough in both the LdT (61.5%) and LVD (46.2%) groups. The proportion of patients with adherence rate (>90%) at year 3 was 90.8% in the ETV group, 83.9% in the LdT group, and 83.9% in the LVD group. Conclusions: Treatment-na?ve CHB patients with a 3-year ETV treatment in Taiwan have the lower likelihood of treatment modification and better rate of adherence compared with those with LdT or LVD treatment. ? 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897607632&doi=10.1111%2fjgh.12416&partnerID=40&md5=3f4defb36088a136ef763ee8e427d3fe https://scholars.lib.ntu.edu.tw/handle/123456789/581989 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.12416 | SDG/Keyword: | entecavir; lamivudine; telbivudine; virus DNA; adolescent; adult; aged; article; chronic hepatitis; demography; drug efficacy; female; follow up; hepatitis B; Hepatitis B virus; human; incidence; long term care; maintenance therapy; major clinical study; male; middle aged; observational study; patient compliance; priority journal; Taiwan; treatment modification; treatment outcome; treatment refusal; unspecified side effect; very elderly; young adult; chronic hepatitis B; entecavir; lamivudine; patient adherence; telbivudine; Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Dihydropyridines; Female; Follow-Up Studies; Guanine; Hepatitis B; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Prospective Studies; Taiwan; Time Factors; Young Adult [SDGs]SDG3 |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.